Shares of Solaris Resources Inc. (CVE:SLS – Get Free Report) were down 2.7% during mid-day trading on Friday . The company traded as low as C$5.95 and last traded at C$6.15. Approximately 53,313 shares were traded during trading, a decline of 60% from the average daily volume of 132,199 shares. The stock had previously closed at C$6.32.
Solaris Resources Stock Performance
The business’s 50 day moving average is C$6.15 and its two-hundred day moving average is C$6.15.
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Featured Stories
- Five stocks we like better than Solaris Resources
- 3 Stocks to Consider Buying in October
- Pfizer is Locking in New Growth Through a New Acquisition
- Investing In Preferred Stock vs. Common Stock
- Copper Giant Freeport Slumps but Analysts See 33% Upside
- Golden Cross Stocks: Pattern, Examples and Charts
- The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
